As of 2016, there are 10 active principles approved which are: Two interferons (interferon beta-1a and interferon beta-1b), glatiramer acetate, mitoxantrone, fingolimod, teriflunomide,[REF] dimethyl fumarate[REF] and finally three monoclonal antibodies (natalizumab, alemtuzumab[REF] and since May 2016 daclizumab[REF][REF]) .
Mitoxantrone & Copaxone: A recent study in the United Kingdom revealed interesting results when using a combination of mitoxantrone and copaxone.